Maxim Group analyst Jason McCarthy has maintained their bullish stance on ATNM stock, giving a Buy rating on March 12.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jason McCarthy has given his Buy rating due to a combination of factors related to Actinium Pharmaceuticals’ strategic advancements in cancer treatment. The company has initiated a promising Phase 1 trial for a triplet combination therapy in frontline acute myeloid leukemia (AML) under a Cooperative Research and Development Agreement with the National Cancer Institute. This trial involves Actimab-A combined with venetoclax and ASTX-727, a novel hypomethylating agent, which could offer advantages over current standard treatments.
The decision to move Actimab-A to frontline AML is supported by positive prior data in relapsed/refractory AML, showcasing the drug’s potential in challenging patient populations, including those with TP53 mutations. Actimab-A’s unique mechanism, utilizing targeted radiotherapy with Actinium-225, provides a highly precise approach to cancer treatment, potentially leading to better patient outcomes. These strategic developments and the promising early results underpin McCarthy’s confidence in Actinium Pharmaceuticals’ future prospects, justifying the Buy rating.
In another report released on March 12, JonesTrading also maintained a Buy rating on the stock with a $9.00 price target.